India Validates Its First Home-Grown HPV Test, Setting a Global Benchmark for Cheaper Cervical-Cancer Screening

India has clinically validated its first indigenous HPV DNA test for cervical-cancer screening — and in doing so set a new global precedent. Molbio Diagnostics' Truenat HPV-HR Plus has met the rigorous performance criteria laid down by the International Agency for Research on Cancer (IARC), the World Health Organization's specialised cancer research arm, according to a multicentre study published in the International Journal of Cancer.

The world's first validated "reduced-valency" test

What makes the result notable beyond India is the kind of test that was validated. Conventional HPV DNA tests screen for around 14 high-risk strains of the human papillomavirus. Truenat HPV-HR Plus deliberately narrows that to the eight most carcinogenic strains — a "reduced-valency" design. The new study is described as the world's first formal validation of a reduced-valency HPV test against international standards, effectively establishing a scientific benchmark for evaluating this leaner, lower-cost class of screening tools.

On the numbers that matter to clinicians, the test cleared the bar comfortably. Against the IARC criteria it recorded a relative sensitivity of 1.03 for detecting CIN2+ lesions and 1.00 for CIN3+ lesions — the precancerous changes that screening is meant to catch — while holding a relative clinical specificity of 0.99, meaning it does not over-flag healthy women.

Why a domestic, point-of-care test matters

Cervical cancer remains one of the leading causes of cancer death among Indian women, despite being highly preventable when precancerous changes are caught early. The obstacles have been practical: imported HPV tests are expensive, and lab-based platforms are concentrated in cities, far from the rural populations most at risk.

The Truenat system is built around portable, battery-capable molecular testing devices already widely deployed across India for diseases such as tuberculosis. Running an HPV assay on that same decentralised, point-of-care platform means screening can move out of central laboratories and into primary health centres and field camps — exactly where India's national screening ambitions need it to reach. A validated indigenous test also sidesteps import costs and supply dependencies, which is what makes population-scale screening financially plausible.

A model for low-resource countries

Because the validated test is both affordable and designed for decentralised use, public-health researchers have framed it as a template that other low- and middle-income countries could adopt. The WHO has set global targets to eliminate cervical cancer as a public-health problem, and screening coverage is a central pillar of that strategy. A test that meets WHO-IARC standards while being cheaper and easier to deploy directly addresses the coverage gap that has held many countries back.

Built on a public-research collaboration

The validation was not a single-company effort. The multicentre study drew on AIIMS New Delhi, the ICMR-National Institute of Cancer Prevention and Research, the ICMR-National Institute for Research in Reproductive and Child Health, the IARC in France, and the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology — a mix of clinical, epidemiological and translational-funding institutions that mirrors how India increasingly tries to push home-grown diagnostics from bench to field.

Validation is a milestone, not the finish line: rolling the test into routine programmes will depend on procurement, training and screening logistics across India's vast and uneven health system. But with an internationally benchmarked, indigenously made HPV test now in hand, the country has cleared one of the harder technical hurdles standing between it and large-scale cervical-cancer prevention.

Sources

• India validates first indigenous HPV DNA test for cervical cancer screening — Indian Pharma Post
• India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test — Indian Pharma Post
• India's validated HPV test to offer cervical cancer screening model for low-resource countries — BioSpectrum India
• India successfully validates the first indigenous HPV test for Cervical Cancer screening — IndiaMedToday
• India validates first indigenous HPV test — Medical Buyer